Latest news with #BristolMyersSquibb
Yahoo
7 hours ago
- Business
- Yahoo
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. The company has dealt with some hurdles in the past, but it has secured several key new drug approvals in recent years. One of the most notable is Reblozyl, a treatment for anemia in individuals with beta-thalassemia, a rare blood disorder. In the first quarter, Reblozyl generated $478 million in sales, marking a 35% increase compared to the same period last year. Bristol-Myers Squibb Company (NYSE:BMY)'s revenue for the year came in at $11.2 billion, which, though, fell by 5.6% from the same period last year, beat analysts' estimates by $494.6 million. The company's cash position also remained strong, with cash and cash equivalents of $10.9 billion, up from $10.34 billion at the end of December 2024. Bristol-Myers Squibb Company (NYSE:BMY) has raised its full-year revenue forecast from around $45.5 billion to a new range of about $45.8 billion to $46.8 billion. This upward revision reflects strong results from its Growth Portfolio, stronger-than-anticipated Legacy Portfolio sales in the first quarter of 2025, and a positive foreign exchange impact of roughly $500 million. Bristol-Myers Squibb Company (NYSE:BMY) offers a quarterly dividend of $0.62 per share and has a dividend yield of 5.18%, as of July 17. The company has been rewarding its shareholders with growing dividends for the past 16 years. While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
7 hours ago
- Business
- Yahoo
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. The company has dealt with some hurdles in the past, but it has secured several key new drug approvals in recent years. One of the most notable is Reblozyl, a treatment for anemia in individuals with beta-thalassemia, a rare blood disorder. In the first quarter, Reblozyl generated $478 million in sales, marking a 35% increase compared to the same period last year. Bristol-Myers Squibb Company (NYSE:BMY)'s revenue for the year came in at $11.2 billion, which, though, fell by 5.6% from the same period last year, beat analysts' estimates by $494.6 million. The company's cash position also remained strong, with cash and cash equivalents of $10.9 billion, up from $10.34 billion at the end of December 2024. Bristol-Myers Squibb Company (NYSE:BMY) has raised its full-year revenue forecast from around $45.5 billion to a new range of about $45.8 billion to $46.8 billion. This upward revision reflects strong results from its Growth Portfolio, stronger-than-anticipated Legacy Portfolio sales in the first quarter of 2025, and a positive foreign exchange impact of roughly $500 million. Bristol-Myers Squibb Company (NYSE:BMY) offers a quarterly dividend of $0.62 per share and has a dividend yield of 5.18%, as of July 17. The company has been rewarding its shareholders with growing dividends for the past 16 years. While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Business
- Yahoo
Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program
Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer, Inc. (NYSE:PFE) have announced a direct-to-patient program for Eliquis (apixaban), their top-selling blood thinner, in a move aimed at improving access for uninsured and underinsured patients. Starting September 8, 2025, eligible individuals will be able to purchase a 30-day supply of Eliquis for approximately $346, more than 40% below the current list price of $606, through a new subscription-based model that includes direct shipping and personalized support. A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. The initiative, called Eliquis 360 Support, will be available in all U.S. states and Puerto Rico. It will also provide patients with help navigating insurance options and educational resources for managing cardiovascular conditions. Eliquis, widely prescribed to prevent stroke and treat deep vein thrombosis, generated over $11 billion in global sales last year and remains one of the most important assets in the portfolios of both companies. This marks a significant shift in drug distribution strategy, aligning with broader industry trends toward transparency and affordability. While the new price still exceeds the $231 monthly Medicare-negotiated rate that will take effect in 2026, the companies are preemptively responding to mounting political and regulatory scrutiny over drug costs. It also follows similar direct-to-patient initiatives launched by rivals such as Eli Lilly and Novo Nordisk. Although most current Eliquis users are insured, the move helps both companies position themselves as proactive on affordability while potentially defending prescription volume as generic competition looms. For Pfizer and Bristol Myers, it's a strategic play that reflects evolving market and policy pressures. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. This article is originally published at Insider Monkey. Inicia sesión para acceder a tu portafolio
Yahoo
13 hours ago
- Business
- Yahoo
Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program
Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer, Inc. (NYSE:PFE) have announced a direct-to-patient program for Eliquis (apixaban), their top-selling blood thinner, in a move aimed at improving access for uninsured and underinsured patients. Starting September 8, 2025, eligible individuals will be able to purchase a 30-day supply of Eliquis for approximately $346, more than 40% below the current list price of $606, through a new subscription-based model that includes direct shipping and personalized support. A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. The initiative, called Eliquis 360 Support, will be available in all U.S. states and Puerto Rico. It will also provide patients with help navigating insurance options and educational resources for managing cardiovascular conditions. Eliquis, widely prescribed to prevent stroke and treat deep vein thrombosis, generated over $11 billion in global sales last year and remains one of the most important assets in the portfolios of both companies. This marks a significant shift in drug distribution strategy, aligning with broader industry trends toward transparency and affordability. While the new price still exceeds the $231 monthly Medicare-negotiated rate that will take effect in 2026, the companies are preemptively responding to mounting political and regulatory scrutiny over drug costs. It also follows similar direct-to-patient initiatives launched by rivals such as Eli Lilly and Novo Nordisk. Although most current Eliquis users are insured, the move helps both companies position themselves as proactive on affordability while potentially defending prescription volume as generic competition looms. For Pfizer and Bristol Myers, it's a strategic play that reflects evolving market and policy pressures. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
17 hours ago
- Business
- Reuters
Bristol Myers drug fails main goal in cancer-linked anemia trial
July 18 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main goal of a late-stage trial to treat anemia caused by a rare bone marrow cancer. The study did not achieve statistically significant results in helping patients with myelofibrosis become free from red blood cell transfusions for any 12-week period during the first 24 weeks of treatment. The miss could signal long-term challenges for the company as future revenues rely on expanding the use of key drugs, Raymond James analysts said. They noted several missed opportunities for broader approvals, including Sotyktu in ulcerative colitis and Crohn's, Camzyos in heart disease, Opdualag in early-stage melanoma, and Cobenfy in schizophrenia. The company, however, remained upbeat about the drug's prospects and said more patients receiving Reblozyl saw a reduction in the number of transfusions needed and an increase in hemoglobin levels, a key measure of anemia. The side effects seen in the trial were similar to those previously reported for Reblozyl. "It is promising to see that Reblozyl led to clinically relevant improvement of anemia for patients with myelofibrosis," said Anne Kerber, head of hematology, oncology, and cell therapy at Bristol Myers. Reblozyl is already approved for certain types of anemia related to other blood disorders, including myelodysplastic syndromes and beta-thalassemia. Bristol Myers recorded $1.77 billion in global sales of Reblozyl in 2024. The late-stage trial in myelofibrosis patients tested Reblozyl with a Janus kinase inhibitor drug, a class of medicines that works by slowing down the immune system. Myelofibrosis is a type of cancer that scars the bone marrow, inhibiting production of healthy blood cells. Reblozyl's failure in the trial might be positive for Disc Medicine (IRON.O), opens new tab, as investors might look favorably at its hepcidin portfolio, given the strength of data and limited treatment options, BMO Capital Markets analysts said. Shares of Disc Medicine rose 4%, while Bristol Myers slipped 1% in morning trading.
